Öz
Amaç:
Sıçan retina hücrelerinde intravitreal bevacizumabın apoptotik etkilerinin incelenmesi.
Gereç ve Yöntem:
Otuz altı erişkin erkek İsviçre-Albino sıçan randomize olarak iki gruba bölündü. İlk gruba 0,01ml salin içinde 0,25mg bevacizumab , ikinci gruba aynı miktar salin intravitreal olarak uygulandı. Her grup üç alt gruba ayrıldı. Hayvanlar deneyin 3, 24 ve 72inci saatlerinde feda edildi ve göz küreleri enüklee edildi. Enüklee gözler histolojik analiz, kaspaz-3, kaspaz-8, kaspaz-9, Fas/Fas L, VEGF ve VEGF reseptörleri (Flt-1, Flk-1) ve TUNEL boyama için hazırlandı.
Sonuçlar:
Histolojik değerlendirme her iki grupta da retinal toksisite işaretleri göstermedi. TUNEL boyamada, TUNEL (+) hücreler tüm alt gruplarda izlendi, ancak pozitif hücre sayısı bevacizumab tedavi grubunda tedavinin 24 ve 72 inci saatlerinde istatistiksel anlamlı düzeye erişecek derecede göreceli olarak daha düşüktü (p<0,001). İmmünhistokimyasal analizler sonucunda salin ile tedavi gören alt gruplarda apoptoz indükleyen proteinlerin immünreaktivitesinin bevacizumab uygulanan gruba göre daha belirgin olduğu ortaya çıktı. VEGF immünreaktivitesi de salin uygulanan grupta belirgindi. VEGF reseptörleri için boyanma sadece Flt-1 için kontrol grubunda üçüncü saatte pozitifti.
Tartışma:
Bevacizumab kontrol grubu ile karşılaştırıldığında TUNEL ve immünohistokimyasal boyamalarda kısa dönemde apoptotik indüksiyon potansiyeline sahip değildir.
Anahtar Kelimeler: Apoptozis, bevacizumab, kaspaz, VEGF
Kaynakça
Hussain N, Ghanekar Y, Kaur I. The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. Indian J Ophthalmol. 2007; 55:445-50.
Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008 ;246:81-7.
Ferarara N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocrine Reviews. 2004; 25: 581-611.
Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-5.
Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336-9.
Nyugen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol. 2005;89:1368-70.
Mason JO, Albert MA, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina. 2006;26:356-7.
Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-8.
Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279-84.
Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-9.
Kaempf S, Johnen S, Salz AK, Weinberger A, Walter P, Thumann G. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci. 2008 ;49:3164-71.
Yong-hao L, Ye-hong Z, Lin L, et al. Caspase-dependent retinal ganglion cell apoptosis in the rat model of acute diabetes. Chin Med J 2008;121:2566-71.
Stefanis L. Caspase-dependent and -independent neuronal death: two distinct pathways to neuronal injury. Neuroscientist. 2005 ;11:50-62.
Congdon N, O’Colmain B, Klaver CC, et al. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-85.
Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina. 2006 ;26:512-8.
Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111-8.
Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-34.
Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-47.
Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol. 2005;89:1368-70.
Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol. 2007;245:1837-42.
Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008 ;49:4523-7.
Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006;90;1542-7.
Peters S, Julien S, Heiduschka P, et al. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol. 2007;91:827-31.
Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53-67.
van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ, Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death and Differentiation 2002;9:1031-42.
Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. 1998 22; 273:13313-6.
Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development 1999;126:1149-59.
Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103:159-65.
Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci. 2007;48:1773-81.
Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-9.
Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26: 270-4.
Manzano RPA, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257-61.
Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18:502-8.
Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of Histologic Retinal Toxicity of Intravitreal Bevacizumab in a Rabbit Model. Am J Ophthalmol. 2006;142:162-4.
Kaempf S, Johnen S, Salz AK, Weinberger A, Walter P, Thumann G. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci. 2008 ;49:3164-71.
Spitzer MS, Wallenfels-Thilo B, Sierra A. et al. Tuebingen Bevacizumab Study Group. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006 ;90:1316-21.
Avci B, Avci R, Inan UU, Kaderli B. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Invest Ophthalmol Vis Sci. 2009;50:3438-46.
